|
|
EphB4 protein serves as a sentry for tumor cells
Jul 1, 2006, 03:49, Reviewed by: Dr. Priya Saxena
|
|
"There are certain growth factors that can make this particular protein (EphB4) go up. We are learning more about how this protein is turned on and off in a cancer cell."
|
By University of Southern California,
A protein that allows breast cancer cells to evade the body's natural immune responses could be a target of future cancer therapies, according to a study by scientists from the Keck School of Medicine of the University of Southern California.
The study, published in the July 1 issue of the American Journal of Pathology, is the first to identify how EphB4 � a protein that sits on the surface of cells � functions.
"The important aspect of this study is that � if we turn the protein [EphB4] off, the tumor cells die, which means that its function helps the cancer cells survive," says Parkash S. Gill, MD, a professor of medicine in the Keck School and the study's senior author.
The scientists used a fluorescent dye attached to the protein's antibody to reveal the protein's location on the tumor cells.
"The first step was to identify whether it's there [on cancer cells] and how often," he explained. "We found that it was present on 60 percent of the tumors � and it's expressed from the very first stage of the cancer formation."
The next step was to determine EphB4's purpose. What the scientists discovered was that EphB4 serves as a sentry, guarding the tumor cells from any defenses the body deploys to attack them.
"There are means in the body to kill tumor cells," Gill says. "[If] you block those then you give the cells the opportunity to survive and grow." Not only did EphB4 block those defenses, but it helped the cancer cells flourish by issuing a call for more blood vessels � the biological equivalent of food for the tumor.
"The tumor cell carrying this protein � on its surface communicates with blood vessels nearby," Gill says. "It sends the signal for more blood vessels to grow. One key item for any cancer to grow is to include more blood vessels."
The goal of a future anti-cancer therapy would be to block the protein, essentially knocking out one of the tumor cell's guardians. A similar approach was used to develop Herceptin, one of the first biological treatments for breast cancer. Herceptin targets the her2 protein, which is found on the surface of tumor cells about 20 percent of the time, says Gill.
The her2 protein played a role in this study as well. That protein, along with several of its cousins, was found to activate EphB4, he said. "There are certain growth factors that can make this particular protein (EphB4) go up," Gill says. "We are learning more about how this protein is turned on and off in a cancer cell." 
- July 1 issue of the American Journal of Pathology
www.usc.edu
The other Keck School researchers and study's authors were S. Ram Kumar, Jasbir Singh, Guangbin Xia, Eric J. Ley, Jeffrey Scehnet, Neil G. Kumar, Debra Hawes, Michael F. Press and Fred A. Weaver. Valery Krasnoperov and Loubna Hassanieh from VasGene Inc. also contributed to the paper.
The study was funded by the Entertainment Industry Foundation's Women's Cancer Research Fund and the National Institutes of Health.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
